Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

372 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
[HRT in post menopausal women and breast cancer at the Institut Curie].
Czernichow C, This P, Asselain B, Falcou MC, Savignoni A, Salmon RJ; Groupe sein de l'Institut Curie, Sigal-Zafrani B. Czernichow C, et al. Among authors: asselain b. Bull Cancer. 2007 May;94(5):469-75. Bull Cancer. 2007. PMID: 17535785 Free article. French.
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
Kerbrat P, Desmoulins I, Roca L, Levy C, Lortholary A, Marre A, Delva R, Rios M, Viens P, Brain É, Serin D, Edel M, Debled M, Campone M, Mourret-Reynier MA, Bachelot T, Foucher-Goudier MJ, Asselain B, Lemonnier J, Martin AL, Roché H. Kerbrat P, et al. Among authors: asselain b. Eur J Cancer. 2017 Jul;79:166-175. doi: 10.1016/j.ejca.2017.03.004. Epub 2017 May 11. Eur J Cancer. 2017. PMID: 28501763 Clinical Trial.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H. Penault-Llorca F, et al. Among authors: asselain b. BMC Cancer. 2018 May 4;18(1):526. doi: 10.1186/s12885-018-4331-8. BMC Cancer. 2018. PMID: 29728098 Free PMC article.
372 results